Logo image of SUPN

SUPERNUS PHARMACEUTICALS INC (SUPN) Stock Fundamental Analysis

NASDAQ:SUPN - Nasdaq - US8684591089 - Common Stock - Currency: USD

32.34  -1.25 (-3.72%)

After market: 32.34 0 (0%)

Fundamental Rating

7

Taking everything into account, SUPN scores 7 out of 10 in our fundamental rating. SUPN was compared to 193 industry peers in the Pharmaceuticals industry. Both the health and profitability get an excellent rating, making SUPN a very profitable company, without any liquidiy or solvency issues. SUPN scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings would make SUPN suitable for value and quality investing!


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

SUPN had positive earnings in the past year.
SUPN had a positive operating cash flow in the past year.
Each year in the past 5 years SUPN has been profitable.
Each year in the past 5 years SUPN had a positive operating cash flow.
SUPN Yearly Net Income VS EBIT VS OCF VS FCFSUPN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

1.2 Ratios

SUPN has a better Return On Assets (4.60%) than 88.08% of its industry peers.
SUPN's Return On Equity of 6.01% is amongst the best of the industry. SUPN outperforms 86.01% of its industry peers.
SUPN has a Return On Invested Capital of 4.82%. This is amongst the best in the industry. SUPN outperforms 82.38% of its industry peers.
SUPN had an Average Return On Invested Capital over the past 3 years of 2.70%. This is significantly below the industry average of 14.87%.
The last Return On Invested Capital (4.82%) for SUPN is above the 3 year average (2.70%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 4.6%
ROE 6.01%
ROIC 4.82%
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
SUPN Yearly ROA, ROE, ROICSUPN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

SUPN has a Profit Margin of 9.27%. This is amongst the best in the industry. SUPN outperforms 86.53% of its industry peers.
In the last couple of years the Profit Margin of SUPN has declined.
SUPN's Operating Margin of 12.49% is amongst the best of the industry. SUPN outperforms 83.42% of its industry peers.
SUPN's Operating Margin has declined in the last couple of years.
SUPN's Gross Margin of 89.75% is amongst the best of the industry. SUPN outperforms 93.26% of its industry peers.
SUPN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 12.49%
PM (TTM) 9.27%
GM 89.75%
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
SUPN Yearly Profit, Operating, Gross MarginsSUPN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

7

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so SUPN is destroying value.
The number of shares outstanding for SUPN has been increased compared to 1 year ago.
SUPN has more shares outstanding than it did 5 years ago.
There is no outstanding debt for SUPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SUPN Yearly Shares OutstandingSUPN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
SUPN Yearly Total Debt VS Total AssetsSUPN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

An Altman-Z score of 5.19 indicates that SUPN is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.19, SUPN belongs to the top of the industry, outperforming 80.31% of the companies in the same industry.
SUPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 5.19
ROIC/WACC0.48
WACC9.97%
SUPN Yearly LT Debt VS Equity VS FCFSUPN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.3 Liquidity

SUPN has a Current Ratio of 2.44. This indicates that SUPN is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of SUPN (2.44) is comparable to the rest of the industry.
SUPN has a Quick Ratio of 2.26. This indicates that SUPN is financially healthy and has no problem in meeting its short term obligations.
SUPN has a Quick ratio (2.26) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.44
Quick Ratio 2.26
SUPN Yearly Current Assets VS Current LiabilitesSUPN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

6

3. Growth

3.1 Past

SUPN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 98.54%, which is quite impressive.
Measured over the past 5 years, SUPN shows a small growth in Earnings Per Share. The EPS has been growing by 3.78% on average per year.
SUPN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.81%.
SUPN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.00% yearly.
EPS 1Y (TTM)98.54%
EPS 3Y37.36%
EPS 5Y3.78%
EPS Q2Q%69.23%
Revenue 1Y (TTM)11.81%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%4.3%

3.2 Future

The Earnings Per Share is expected to grow by 15.42% on average over the next years. This is quite good.
Based on estimates for the next years, SUPN will show a small growth in Revenue. The Revenue will grow by 7.28% on average per year.
EPS Next Y-31.87%
EPS Next 2Y-2.58%
EPS Next 3Y10.68%
EPS Next 5Y15.42%
Revenue Next Year-0.44%
Revenue Next 2Y5.61%
Revenue Next 3Y7.56%
Revenue Next 5Y7.28%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
SUPN Yearly Revenue VS EstimatesSUPN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
SUPN Yearly EPS VS EstimatesSUPN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2 4 6

7

4. Valuation

4.1 Price/Earnings Ratio

SUPN is valuated reasonably with a Price/Earnings ratio of 11.89.
SUPN's Price/Earnings ratio is rather cheap when compared to the industry. SUPN is cheaper than 89.12% of the companies in the same industry.
When comparing the Price/Earnings ratio of SUPN to the average of the S&P500 Index (27.50), we can say SUPN is valued rather cheaply.
With a Price/Forward Earnings ratio of 13.42, SUPN is valued correctly.
SUPN's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. SUPN is cheaper than 79.79% of the companies in the same industry.
SUPN's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 36.44.
Industry RankSector Rank
PE 11.89
Fwd PE 13.42
SUPN Price Earnings VS Forward Price EarningsSUPN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

93.26% of the companies in the same industry are more expensive than SUPN, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of SUPN indicates a rather cheap valuation: SUPN is cheaper than 89.64% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 11.09
EV/EBITDA 6.54
SUPN Per share dataSUPN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

SUPN has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)3.15
EPS Next 2Y-2.58%
EPS Next 3Y10.68%

0

5. Dividend

5.1 Amount

No dividends for SUPN!.
Industry RankSector Rank
Dividend Yield N/A

SUPERNUS PHARMACEUTICALS INC

NASDAQ:SUPN (7/18/2025, 8:14:13 PM)

After market: 32.34 0 (0%)

32.34

-1.25 (-3.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)07-31 2025-07-31/amc
Inst Owners108.96%
Inst Owner Change0%
Ins Owners4.08%
Ins Owner Change2.14%
Market Cap1.81B
Analysts78.18
Price Target39.78 (23.01%)
Short Float %9.12%
Short Ratio8.34
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.36%
Min EPS beat(2)15.55%
Max EPS beat(2)77.18%
EPS beat(4)3
Avg EPS beat(4)60.49%
Min EPS beat(4)-9.5%
Max EPS beat(4)158.74%
EPS beat(8)5
Avg EPS beat(8)41.41%
EPS beat(12)6
Avg EPS beat(12)18.01%
EPS beat(16)9
Avg EPS beat(16)24.4%
Revenue beat(2)1
Avg Revenue beat(2)4.64%
Min Revenue beat(2)-0.71%
Max Revenue beat(2)9.98%
Revenue beat(4)3
Avg Revenue beat(4)7.41%
Min Revenue beat(4)-0.71%
Max Revenue beat(4)10.86%
Revenue beat(8)5
Avg Revenue beat(8)3.48%
Revenue beat(12)8
Avg Revenue beat(12)2.47%
Revenue beat(16)11
Avg Revenue beat(16)2.27%
PT rev (1m)0.52%
PT rev (3m)0.52%
EPS NQ rev (1m)-6%
EPS NQ rev (3m)2.92%
EPS NY rev (1m)-18.23%
EPS NY rev (3m)-13.58%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.1%
Revenue NY rev (1m)2.26%
Revenue NY rev (3m)2.62%
Valuation
Industry RankSector Rank
PE 11.89
Fwd PE 13.42
P/S 2.71
P/FCF 11.09
P/OCF 11.03
P/B 1.76
P/tB 4.4
EV/EBITDA 6.54
EPS(TTM)2.72
EY8.41%
EPS(NY)2.41
Fwd EY7.45%
FCF(TTM)2.92
FCFY9.02%
OCF(TTM)2.93
OCFY9.07%
SpS11.93
BVpS18.41
TBVpS7.35
PEG (NY)N/A
PEG (5Y)3.15
Profitability
Industry RankSector Rank
ROA 4.6%
ROE 6.01%
ROCE 7.83%
ROIC 4.82%
ROICexc 8.53%
ROICexgc N/A
OM 12.49%
PM (TTM) 9.27%
GM 89.75%
FCFM 24.45%
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
ROICexc(3y)4.39%
ROICexc(5y)6.6%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)4.82%
ROCE(5y)7.36%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y11.61%
ROICexc growth 5Y-8.56%
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
F-Score8
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 1%
Cap/Sales 0.12%
Interest Coverage -758.75
Cash Conversion 100.39%
Profit Quality 263.83%
Current Ratio 2.44
Quick Ratio 2.26
Altman-Z 5.19
F-Score8
WACC9.97%
ROIC/WACC0.48
Cap/Depr(3y)0.67%
Cap/Depr(5y)5.39%
Cap/Sales(3y)0.09%
Cap/Sales(5y)0.25%
Profit Quality(3y)2940.94%
Profit Quality(5y)1832.68%
High Growth Momentum
Growth
EPS 1Y (TTM)98.54%
EPS 3Y37.36%
EPS 5Y3.78%
EPS Q2Q%69.23%
EPS Next Y-31.87%
EPS Next 2Y-2.58%
EPS Next 3Y10.68%
EPS Next 5Y15.42%
Revenue 1Y (TTM)11.81%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%4.3%
Revenue Next Year-0.44%
Revenue Next 2Y5.61%
Revenue Next 3Y7.56%
Revenue Next 5Y7.28%
EBIT growth 1Y1176.19%
EBIT growth 3Y-5.79%
EBIT growth 5Y-9.43%
EBIT Next Year84.48%
EBIT Next 3Y-11.94%
EBIT Next 5Y21.99%
FCF growth 1Y0.95%
FCF growth 3Y11.03%
FCF growth 5Y4.05%
OCF growth 1Y1.58%
OCF growth 3Y10.6%
OCF growth 5Y3.74%